{"id":"map0004","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a bispecific antibody in development by Allergan, MAP0004 is designed to bridge immune effector cells with tumor cells or tumor-associated antigens, potentially enhancing T-cell activation and recruitment to the tumor microenvironment. The dual-targeting approach aims to overcome resistance mechanisms and improve anti-tumor efficacy compared to single-target approaches.","oneSentence":"MAP0004 is a bispecific antibody that simultaneously engages two distinct molecular targets to enhance immune activation against cancer cells.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:20:08.158Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Solid tumors (specific indication under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT00623636","phase":"PHASE3","title":"Phase 3 Study of MAP0004 in Adult Migraineurs","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-07","conditions":"Migraine Disorders","enrollment":902},{"nctId":"NCT01468558","phase":"PHASE1","title":"Pharmacokinetics & Tolerability Study of MAP0004 Co-administered With Ketoconazole","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-07","conditions":"Healthy","enrollment":24},{"nctId":"NCT01199965","phase":"PHASE1, PHASE2","title":"Pharmacokinetics & Tolerability Study of MAP0004 in Smoking and Non-Smoking Adult Volunteers","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-01","conditions":"Healthy Subjects","enrollment":47},{"nctId":"NCT01089062","phase":"PHASE1","title":"Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-03","conditions":"Healthy","enrollment":24},{"nctId":"NCT01191723","phase":"PHASE1","title":"QT Intervals Study to Compare the Acute Effects of Orally Inhaled Dihydroergotamine (DHE), Oral Moxifloxacin, and Placebo","status":"COMPLETED","sponsor":"Allergan","startDate":"2010-08","conditions":"Healthy","enrollment":54}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"MAP0004","genericName":"MAP0004","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"MAP0004 is a bispecific antibody that simultaneously engages two distinct molecular targets to enhance immune activation against cancer cells. Used for Solid tumors (specific indication under investigation in Phase 3).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}